81490
|
AUTOIMMUNE (RHEUMATOID ARTHRITIS), ANALYSIS OF 12 BIOMARKERS USING IMMUNOASSAYS, UTILIZING SERUM, PROGNOSTIC ALGORITHM REPORTED AS A DISEASE ACTIVITY SCORE
|
81500
|
ONCOLOGY (OVARIAN), BIOCHEMICAL ASSAYS OF TWO PROTEINS (CA-125 AND HE4), UTILIZING SERUM, WITH MENOPAUSAL STATUS, ALGORITHM REPORTED AS A RISK SCORE
|
81503
|
ONCOLOGY (OVARIAN), BIOCHEMICAL ASSAYS OF FIVE PROTEINS (CA-125, APOLIPOPROTEIN A1, BETA-2 MICROGLOBULIN, TRANSFERRIN, AND PRE-ALBUMIN), UTILIZING SERUM, ALGORITHM REPORTED AS A RISK SCORE
|
81517
|
LIVER DISEASE, ANALYSIS OF 3 BIOMARKERS (HYALURONIC ACID [HA], PROCOLLAGEN III AMINO TERMINAL PEPTIDE [PIIINP], TISSUE INHIBITOR OF METALLOPROTEINASE 1 [TIMP-1]), USING IMMUNOASSAYS, UTILIZING SERUM, PROGNOSTIC ALGORITHM REPORTED AS A RISK SCORE AND RISK OF LIVER FIBROSIS AND LIVER-RELATED CLINICAL EVENTS WITHIN 5 YEARS
|
81539
|
ONCOLOGY (HIGH-GRADE PROSTATE CANCER), BIOCHEMICAL ASSAY OF FOUR PROTEINS (TOTAL PSA, FREE PSA, INTACT PSA, AND HUMAN KALLIKREIN-2 [HK2]), UTILIZING PLASMA OR SERUM, PROGNOSTIC ALGORITHM REPORTED AS A PROBABILITY SCORE
|
81599
|
UNLISTED MULTIANALYTE ASSAY WITH ALGORITHMIC ANALYSIS
|
0002M
|
LIVER DISEASE, TEN BIOCHEMICAL ASSAYS (ALT, A2-MACROGLOBULIN, APOLIPOPROTEIN A-1, TOTAL BILIRUBIN, GGT, HAPTOGLOBIN, AST, GLUCOSE, TOTAL CHOLESTEROL AND TRIGLYCERIDES) UTILIZING SERUM, PROGNOSTIC ALGORITHM REPORTED AS QUANTITATIVE SCORES FOR FIBROSIS, STEATOSIS AND ALCOHOLIC STEATOHEPATITIS (ASH)
|
0003M
|
LIVER DISEASE, TEN BIOCHEMICAL ASSAYS (ALT, A2-MACROGLOBULIN, APOLIPOPROTEIN A-1, TOTAL BILIRUBIN, GGT, HAPTOGLOBIN, AST, GLUCOSE, TOTAL CHOLESTEROL AND TRIGLYCERIDES) UTILIZING SERUM, PROGNOSTIC ALGORITHM REPORTED AS QUANTITATIVE SCORES FOR FIBROSIS, STEATOSIS AND NONALCOHOLIC STEATOHEPATITIS (NASH)
|
0015M
|
ADRENAL CORTICAL TUMOR, BIOCHEMICAL ASSAY OF 25 STEROID MARKERS, UTILIZING 24-HOUR URINE SPECIMEN AND CLINICAL PARAMETERS, PROGNOSTIC ALGORITHM REPORTED AS A CLINICAL RISK AND INTEGRATED CLINICAL STEROID RISK FOR ADRENAL CORTICAL CARCINOMA, ADENOMA, OR OTHER ADRENAL MALIGNANCY
|
0019M
|
CARDIOVASCULAR DISEASE, PLASMA, ANALYSIS OF PROTEIN BIOMARKERS BY APTAMER-BASED MICROARRAY AND ALGORITHM REPORTED AS 4-YEAR LIKELIHOOD OF CORONARY EVENT IN HIGH-RISK POPULATIONS
|
0002U
|
ONCOLOGY (COLORECTAL), QUANTITATIVE ASSESSMENT OF THREE URINE METABOLITES (ASCORBIC ACID, SUCCINIC ACID AND CARNITINE) BY LIQUID CHROMATOGRAPHY WITH TANDEM MASS SPECTROMETRY (LC-MS/MS) USING MULTIPLE REACTION MONITORING ACQUISITION, ALGORITHM REPORTED AS LIKELIHOOD OF ADENOMATOUS POLYPS
|
0003U
|
ONCOLOGY (OVARIAN) BIOCHEMICAL ASSAYS OF FIVE PROTEINS (APOLIPOPROTEIN A-1, CA 125 II, FOLLICLE STIMULATING HORMONE, HUMAN EPIDIDYMIS PROTEIN 4, TRANSFERRIN), UTILIZING SERUM, ALGORITHM REPORTED AS A LIKELIHOOD SCORE
|
0021U
|
ONCOLOGY (PROSTATE), DETECTION OF 8 AUTOANTIBODIES (ARF 6, NKX3-1, 5'-UTR-BMI1, CEP 164, 3'-UTR-ROPPORIN, DESMOCOLLIN, AURKAIP-1, CSNK2A2), MULTIPLEXED IMMUNOASSAY AND FLOW CYTOMETRY SERUM, ALGORITHM REPORTED AS RISK SCORE
|
0080U
|
ONCOLOGY (LUNG), MASS SPECTROMETRIC ANALYSIS OF GALECTIN-3-BINDING PROTEIN AND SCAVENGER RECEPTOR CYSTEINE-RICH TYPE 1 PROTEIN M130, WITH FIVE CLINICAL RISK FACTORS (AGE, SMOKING STATUS, NODULE DIAMETER, NODULE-SPICULATION STATUS AND NODULE LOCATION), UTILIZING PLASMA, ALGORITHM REPORTED AS A CATEGORICAL PROBABILITY OF MALIGNANCY
|
0092U
|
ONCOLOGY (LUNG), THREE PROTEIN BIOMARKERS, IMMUNOASSAY USING MAGNETIC NANOSENSOR TECHNOLOGY, PLASMA, ALGORITHM REPORTED AS RISK SCORE FOR LIKELIHOOD OF MALIGNANCY
|
0095U
|
EOSINOPHILIC ESOPHAGITIS, EOTAXIN-3 [CCL26 {C-C MOTIF CHEMOKINE LIGAND 26}] AND MAJOR BASIC PROTEIN [PRG2 {PROTEOGLYCAN 2, PRO EOSINOPHIL MAJOR BASIC PROTEIN}], ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISA), SPECIMEN OBTAINED BY ESOPHAGEAL STRING TEST DEVICE, ALGORITHM REPORTED AS PROBABILITY OF ACTIVE OR INACTIVE EOSINOPHILIC ESOPHAGITIS
|
0105U
|
NEPHROLOGY (CHRONIC KIDNEY DISEASE), MULTIPLEX ELECTROCHEMILUMINESCENT IMMUNOASSAY (ECLIA) OF TUMOR NECROSIS FACTOR RECEPTOR 1A, RECEPTOR SUPERFAMILY 2 (TNFR1, TNFR2), AND KIDNEY INJURY MOLECULE-1 (KIM-1) COMBINED WITH LONGITUDINAL CLINICAL DATA, INCLUDING APOL1 GENOTYPE IF AVAILABLE, AND PLASMA (ISOLATED FRESH OR FROZEN), ALGORITHM REPORTED AS PROBABILITY SCORE FOR RAPID KIDNEY FUNCTION DECLINE (RKFD)
|
0117U
|
PAIN MANAGEMENT, ANALYSIS OF 11 ENDOGENOUS ANALYTES (METHYLMALONIC ACID, XANTHURENIC ACID, HOMOCYSTEINE, PYROGLUTAMIC ACID, VANILMANDELATE, 5HYDROXYINDOLEACETIC ACID, HYDROXYMETHYLGLUTARATE, ETHYLMALONATE, 3HYDROXYPROPYL MERCAPTURIC ACID (3-HPMA), QUINOLINIC ACID, KYNURENIC ACID), LCMS/MS, URINE, ALGORITHM REPORTED AS A PAIN-INDEX SCORE WITH LIKELIHOOD OF ATYPICAL BIOCHEMICAL FUNCTION ASSOCIATED WITH PAIN
|
0174U
|
ONCOLOGY (SOLID TUMOR), MASS SPECTROMETRIC 30 PROTEIN TARGETS, FORMALIN-FIXED PARAFFIN-EMBEDDED TISSUE, PROGNOSTIC AND PREDICTIVE ALGORITHM REPORTED AS LIKELY, UNLIKELY, OR UNCERTAIN BENEFIT OF 39 CHEMOTHERAPY AND TARGETED THERAPEUTIC ONCOLOGY AGENTS
|
0206U
|
NEUROLOGY (ALZHEIMER DISEASE); CELL AGGREGATION USING MORPHOMETRIC IMAGING AND PROTEIN KINASE C-EPSILON (PKCE) CONCENTRATION IN RESPONSE TO AMYLOSPHEROID TREATMENT BY ELISA, CULTURED SKIN FIBROBLASTS, EACH REPORTED AS POSITIVE OR NEGATIVE FOR ALZHEIMER DISEASE
|
0207U
|
NEUROLOGY (ALZHEIMER DISEASE); QUANTITATIVE IMAGING OF PHOSPHORYLATED ERK1 AND ERK2 IN RESPONSE TO BRADYKININ TREATMENT BY IN SITU IMMUNOFLUORESCENCE, USING CULTURED SKIN FIBROBLASTS, REPORTED AS A PROBABILITY INDEX FOR ALZHEIMER DISEASE (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE)
|
0228U
|
ONCOLOGY (PROSTATE), MULTIANALYTE MOLECULAR PROFILE BY PHOTOMETRIC DETECTION OF MACROMOLECULES ADSORBED ON NANOSPONGE ARRAY SLIDES WITH MACHINE LEARNING, UTILIZING FIRST MORNING VOIDED URINE, ALGORITHM REPORTED AS LIKELIHOOD OF PROSTATE CANCER
|
0249U
|
ONCOLOGY (BREAST), SEMIQUANTITATIVE ANALYSIS OF 32 PHOSPHOPROTEINS AND PROTEIN ANALYTES, INCLUDES LASER CAPTURE MICRODISSECTION, WITH ALGORITHMIC ANALYSIS AND INTERPRETATIVE REPORT
|
0259U
|
NEPHROLOGY (CHRONIC KIDNEY DISEASE), NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY MEASUREMENT OF MYO-INOSITOL, VALINE, AND CREATININE, ALGORITHMICALLY COMBINED WITH CYSTATIN C (BY IMMUNOASSAY) AND DEMOGRAPHIC DATA TO DETERMINE ESTIMATED GLOMERULAR FILTRATION RATE (GFR), SERUM, QUANTITATIVE
|
0263U
|
NEUROLOGY (AUTISM SPECTRUM DISORDER [ASD]), QUANTITATIVE MEASUREMENTS OF 16 CENTRAL CARBON METABOLITES (IE, A-KETOGLUTARATE, ALANINE, LACTATE, PHENYLALANINE, PYRUVATE, SUCCINATE, CARNITINE, CITRATE, FUMARATE, HYPOXANTHINE, INOSINE, MALATE, S-SULFOCYSTEINE, TAURINE, URATE, AND XANTHINE), LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY (LC-MS/MS), PLASMA, ALGORITHMIC ANALYSIS WITH RESULT REPORTED AS NEGATIVE OR POSITIVE (WITH METABOLIC SUBTYPES OF ASD)
|
0295U
|
ONCOLOGY (BREAST DUCTAL CARCINOMA IN SITU), PROTEIN EXPRESSION PROFILING BY IMMUNOHISTOCHEMISTRY OF 7 PROTEINS (COX2, FOXA1, HER2, KI-67, P16, PR, SIAH2), WITH 4 CLINICOPATHOLOGIC FACTORS (SIZE, AGE, MARGIN STATUS, PALPABILITY), UTILIZING FORMALIN-FIXED PARAFFIN-EMBEDDED (FFPE) TISSUE, ALGORITHM REPORTED AS A RECURRENCE RISK SCORE
|
0308U
|
CARDIOLOGY (CORONARY ARTERY DISEASE [CAD]), ANALYSIS OF 3 PROTEINS (HIGH SENSITIVITY [HS] TROPONIN, ADIPONECTIN, AND KIDNEY INJURY MOLECULE-1 [KIM-1]) WITH 3 CLINICAL PARAMETERS (AGE, SEX, HISTORY OF CARDIAC INTERVENTION), PLASMA, ALGORITHM REPORTED AS A RISK SCORE FOR OBSTRUCTIVE CAD
|
0309U
|
CARDIOLOGY (CARDIOVASCULAR DISEASE), ANALYSIS OF 4 PROTEINS (NT-PROBNP, OSTEOPONTIN, TISSUE INHIBITOR OF METALLOPROTEINASE-1 [TIMP-1], AND KIDNEY INJURY MOLECULE-1 [KIM-1]), PLASMA, ALGORITHM REPORTED AS A RISK SCORE FOR MAJOR ADVERSE CARDIAC EVENT
|
0310U
|
PEDIATRICS (VASCULITIS, KAWASAKI DISEASE [KD]), ANALYSIS OF 3 BIOMARKERS (NT-PROBNP, C-REACTIVE PROTEIN, AND T-UPTAKE), PLASMA, ALGORITHM REPORTED AS A RISK SCORE FOR KD
|
0312U
|
AUTOIMMUNE DISEASES (EG, SYSTEMIC LUPUS ERYTHEMATOSUS [SLE]), ANALYSIS OF 8 IGG AUTOANTIBODIES AND 2 CELL-BOUND COMPLEMENT ACTIVATION PRODUCTS USING ENZYME-LINKED IMMUNOSORBENT IMMUNOASSAY (ELISA), FLOW CYTOMETRY AND INDIRECT IMMUNOFLUORESCENCE, SERUM, OR PLASMA AND WHOLE BLOOD, INDIVIDUAL COMPONENTS REPORTED ALONG WITH AN ALGORITHMIC SLE-LIKELIHOOD ASSESSMENT
|
0322U
|
NEUROLOGY (AUTISM SPECTRUM DISORDER [ASD]), QUANTITATIVE MEASUREMENTS OF 14 ACYL CARNITINES AND MICROBIOME-DERIVED METABOLITES, LIQUID CHROMATOGRAPHY WITH TANDEM MASS SPECTROMETRY (LC-MS/MS), PLASMA, RESULTS REPORTED AS NEGATIVE OR POSITIVE FOR RISK OF METABOLIC SUBTYPES ASSOCIATED WITH ASD
|
0344U
|
HEPATOLOGY (NONALCOHOLIC FATTY LIVER DISEASE [NAFLD]), SEMIQUANTITATIVE EVALUATION OF 28 LIPID MARKERS BY LIQUID CHROMATOGRAPHY WITH TANDEM MASS SPECTROMETRY (LC-MS/MS), SERUM, REPORTED AS AT-RISK FOR NONALCOHOLIC STEATOHEPATITIS (NASH) OR NOT NASH
|
0351U
|
INFECTIOUS DISEASE (BACTERIAL OR VIRAL), BIOCHEMICAL ASSAYS, TUMOR NECROSIS FACTORRELATED APOPTOSIS-INDUCING LIGAND (TRAIL), INTERFERON GAMMA-INDUCED PROTEIN-10 (IP10), AND C-REACTIVE PROTEIN, SERUM, OR VENOUS WHOLE BLOOD, ALGORITHM REPORTED AS LIKELIHOOD OF BACTERIAL INFECTION
|
0360U
|
ONCOLOGY (LUNG), ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) OF 7 AUTOANTIBODIES (P53, NY-ESO-1, CAGE, GBU4-5, SOX2, MAGE A4, AND HUD), PLASMA, ALGORITHM REPORTED AS A CATEGORICAL RESULT FOR RISK OF MALIGNANCY
|
0365U
|
ONCOLOGY (BLADDER), ANALYSIS OF 10 PROTEIN BIOMARKERS (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1 AND VEGFA) BY IMMUNOASSAYS, URINE, ALGORITHM REPORTED AS A PROBABILITY OF BLADDER CANCER
|
0366U
|
ONCOLOGY (BLADDER), ANALYSIS OF 10 PROTEIN BIOMARKERS (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1 AND VEGFA) BY IMMUNOASSAYS, URINE, ALGORITHM REPORTED AS A PROBABILITY OF RECURRENT BLADDER CANCER
|
0367U
|
ONCOLOGY (BLADDER), ANALYSIS OF 10 PROTEIN BIOMARKERS (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1 AND VEGFA) BY IMMUNOASSAYS, URINE, DIAGNOSTIC ALGORITHM REPORTED AS A RISK SCORE FOR PROBABILITY OF RAPID RECURRENCE OF RECURRENT OR PERSISTENT CANCER FOLLOWING TRANSURETHRAL RESECTION
|
0375U
|
ONCOLOGY (OVARIAN), BIOCHEMICAL ASSAYS OF 7 PROTEINS (FOLLICLE STIMULATING HORMONE, HUMAN EPIDIDYMIS PROTEIN 4, APOLIPOPROTEIN A-1, TRANSFERRIN, BETA-2 MACROGLOBULIN, PREALBUMIN [IE, TRANSTHYRETIN], AND CANCER ANTIGEN 125), ALGORITHM REPORTED AS OVARIAN CANCER RISK SCORE
|
0384U
|
NEPHROLOGY (CHRONIC KIDNEY DISEASE), CARBOXYMETHYLLYSINE, METHYLGLYOXAL HYDROIMIDAZOLONE, AND CARBOXYETHYL LYSINE BY LIQUID CHROMATOGRAPHY WITH TANDEM MASS SPECTROMETRY (LC-MS/MS) AND HBA1C AND ESTIMATED GLOMERULAR FILTRATION RATE (GFR), WITH RISK SCORE REPORTED FOR PREDICTIVE PROGRESSION TO HIGH-STAGE KIDNEY DISEASE
|
0385U
|
NEPHROLOGY (CHRONIC KIDNEY DISEASE), APOLIPOPROTEIN A4 (APOA4), CD5 ANTIGEN-LIKE (CD5L), AND INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3 (IGFBP3) BY ENZYME-LINKED IMMUNOASSAY (ELISA), PLASMA, ALGORITHM COMBINING RESULTS WITH HDL, ESTIMATED GLOMERULAR FILTRATION RATE (GFR) AND CLINICAL DATA REPORTED AS A RISK SCORE FOR DEVELOPING DIABETIC KIDNEY DISEASE
|
0387U
|
ONCOLOGY (MELANOMA), AUTOPHAGY AND BECLIN 1 REGULATOR 1 (AMBRA1) AND LORICRIN (AMLO) BY IMMUNOHISTOCHEMISTRY, FORMALIN-FIXED PARAFFIN-EMBEDDED (FFPE) TISSUE, REPORT FOR RISK OF PROGRESSION
|
0407U
|
NEPHROLOGY (DIABETIC CHRONIC KIDNEY DISEASE [CKD]), MULTIPLEX ELECTROCHEMILUMINESCENT IMMUNOASSAY (ECLIA) OF SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR 1 (STNFR1), SOLUBLE TUMOR NECROSIS RECEPTOR 2 (STNFR2), AND KIDNEY INJURY MOLECULE 1 (KIM-1) COMBINED WITH CLINICAL DATA, PLASMA, ALGORITHM REPORTED AS RISK FOR PROGRESSIVE DECLINE IN KIDNEY FUNCTION
|
0412U
|
BETA AMYLOID, AB42/40 RATIO, IMMUNOPRECIPITATION WITH QUANTITATION BY LIQUID CHROMATOGRAPHY WITH TANDEM MASS SPECTROMETRY (LC-MS/MS) AND QUALITATIVE APOE ISOFORM-SPECIFIC PROTEOTYPING, PLASMA COMBINED WITH AGE, ALGORITHM REPORTED AS PRESENCE OR ABSENCE OF BRAIN AMYLOID PATHOLOGY
|
0415U
|
CARDIOVASCULAR DISEASE (ACUTE CORONARY SYNDROME [ACS]), IL-16, FAS, FASLIGAND, HGF, CTACK, EOTAXIN, AND MCP-3 BY IMMUNOASSAY COMBINED WITH AGE, SEX, FAMILY HISTORY, AND PERSONAL HISTORY OF DIABETES, BLOOD, ALGORITHM REPORTED AS A 5-YEAR (DELETED RISK) SCORE FOR ACS
|
0436U
|
ONCOLOGY (LUNG), PLASMA ANALYSIS OF 388 PROTEINS, USING APTAMER-BASED PROTEOMICS TECHNOLOGY, PREDICTIVE ALGORITHM REPORTED AS CLINICAL BENEFIT FROM IMMUNE CHECKPOINT INHIBITOR THERAPY
|
0446U
|
AUTOIMMUNE DISEASES (SYSTEMIC LUPUS ERYTHEMATOSUS [SLE]), ANALYSIS OF 10 CYTOKINE SOLUBLE MEDIATOR BIOMARKERS BY IMMUNOASSAY, PLASMA, INDIVIDUAL COMPONENTS REPORTED WITH AN ALGORITHMIC RISK SCORE FOR CURRENT DISEASE ACTIVITY
|
0447U
|
AUTOIMMUNE DISEASES (SYSTEMIC LUPUS ERYTHEMATOSUS [SLE]), ANALYSIS OF 11 CYTOKINE SOLUBLE MEDIATOR BIOMARKERS BY IMMUNOASSAY, PLASMA, INDIVIDUAL COMPONENTS REPORTED WITH AN ALGORITHMIC PROGNOSTIC RISK SCORE FOR DEVELOPING A CLINICAL FLARE
|
0458U
|
ONCOLOGY (BREAST CANCER), S100A8 AND S100A9, BY ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), TEAR FLUID WITH AGE, ALGORITHM REPORTED AS A RISK SCORE
|
0468U
|
HEPATOLOGY (NONALCOHOLIC STEATOHEPATITIS [NASH]), MIR-34A-5P, ALPHA 2-MACROGLOBULIN, YKL40, HBA1C, SERUM AND WHOLE BLOOD, ALGORITHM REPORTED AS A SINGLE SCORE FOR NASH ACTIVITY AND FIBROSIS
|